[Assessment of granulopoietic function reserve of the bone marrow by means of the Pyrecol-test in granulocytopenias, immature-cell leukoses and patients under antineoplastic agent therapy].
By injection of the irritating substance Pyrecol the granulopoietic reserve of the function of the bone marrow can be judged. In normal test persons the result is after 8 hours an increase of leucocytes to 176%, when the granulocytes increase to 216%. On the other hand the rate of increase in patients with undifferentiated cell leucosis is statistically highly significantly lower (2alpha = 0.01) with 115 or 132%, respectively. A higher ejection function of the bone marrow correlating with the clinical improvement is to be found after a successful therapy with cytostatics. By this the test informatively contributes to dosage and effectiveness of the therapy with cytostatics and to the course of the disease. In 6 patients with granulocytopenia of unclear genesis examined in the result of the Pyrecol-test 5 passager granulocytopenias with favourable clinical course unambiguously distinguished themselves from a pan-myelophthisis with exitus letalis. The test is easily to be performed and has no essential concomitant a-pearances. By the integral functional evidence it represents a rational supplementation of the locally demarcated morphological substrate of the sternal puncture or bone marrow biopsy, respectively.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000380:Agranulocytosis / Q000175:diagnosis*; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001853:Bone Marrow / Q000187:drug effects*; D005260:Female; D006098:Granulocytes / Q000187:drug effects*; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D007962:Leukocytes / Q000187:drug effects*; D008070:Lipopolysaccharides; D008297:Male; D011135:Polysaccharides, Bacterial; D011379:Prognosis
D000970:Antineoplastic Agents; D008070:Lipopolysaccharides; D011135:Polysaccharides, Bacterial; C013662:pyrecol
Beurteilung der granulopoetischen Funktionsreserve des Knochenmarkes mit Hilfe des Pyrecol-Testes bei Granulozytopenien, unreifzelligen Leukosen und Patienten unter Zytostatikatherapie